Cyclophosphamide, Bortezomib and Methylprednisolone (CyBorMe) for the Treatment of AL Amyloidosis: Initial Experience From a Single Center.
AL amyloidosis
CyBorD
CyBorMe
Organ response
Journal
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
ISSN: 0971-4502
Titre abrégé: Indian J Hematol Blood Transfus
Pays: India
ID NLM: 9425818
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
10
09
2020
accepted:
02
02
2021
entrez:
8
11
2021
pubmed:
9
11
2021
medline:
9
11
2021
Statut:
ppublish
Résumé
The use of cyclophosphamide, bortezomib and dexamethasone (CyBorD) is widely accepted in the treatment of AL amyloidosis (AL). Recently, the substitution of dexamethasone by methylprednisolone (CyBorMe) appeared to improve response rates and survival outcomes. All consecutive newly diagnosed AL amyloidosis treated with CyBorMe from 01/19 to 08/20 were evaluated. A historic cohort of patients treated with CyBorD was used for comparison (01/13-08/20). Methylprednisolone was given IV at 500 mg weekly for 4 weeks in the CyBorMe group. 43 patients were treated with CyBorD and 14 with CyBorMe. After a median of 4 cycles of CyBorD and 3 cycles of CyBorMe, Hematological Response was seen in 90.6% and 92.8% of cases, including CR in 28.5% and 35.7%, VGPR in 33.3% and 35.7% and PR in 30.9% and 21.4% for CyBorD and CyBorMe, respectively. Time to first response was faster in the CyBorMe group (4 vs. 6 weeks) and cardiac response was observed in 44% and 31% of patients treated with CyBorMe and CyBorD, respectively. CyBorMe appeared to be efficacious and well tolerated in patients with AL amyloidosis. Prospective studies with CyBorMe in the stage III/IV group are warranted aiming to minimize toxicity.
Identifiants
pubmed: 34744351
doi: 10.1007/s12288-021-01406-z
pii: 1406
pmc: PMC8523610
doi:
Types de publication
Journal Article
Langues
eng
Pagination
675-678Informations de copyright
© Indian Society of Hematology and Blood Transfusion 2021.
Références
Cancer Control. 2003 Sep-Oct;10(5):361-9
pubmed: 14581890
Blood Rev. 2020 Mar;40:100636
pubmed: 31706583
Haematologica. 2018 Apr;103(4):e165-e168
pubmed: 29305414
J Clin Oncol. 2012 Dec 20;30(36):4541-9
pubmed: 23091105
Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e79-84
pubmed: 27101985
Blood. 2015 Jul 30;126(5):612-5
pubmed: 25987656
Am J Hematol. 2005 Aug;79(4):319-28
pubmed: 16044444
Indian J Hematol Blood Transfus. 2018 Apr;34(2):216-226
pubmed: 29622862
J Clin Oncol. 2011 May 10;29(14):1924-33
pubmed: 21483018
Blood. 2012 May 10;119(19):4391-4
pubmed: 22331188
Blood. 2013 Apr 25;121(17):3420-7
pubmed: 23479568
Am Fam Physician. 1998 Aug;58(2):443-50
pubmed: 9713398
Blood. 2012 May 10;119(19):4387-90
pubmed: 22331187
Clin Lymphoma Myeloma Leuk. 2020 Jun;20(6):394-399
pubmed: 32146104
Blood. 2019 Dec 19;134(25):2271-2280
pubmed: 31578202
Sci Rep. 2019 Jun 12;9(1):8552
pubmed: 31189919